These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36547945)

  • 21. Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.
    Jones JO; Smyth EC
    Cancer Treat Rev; 2020 Mar; 84():101950. PubMed ID: 31918022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
    Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
    Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
    Zheng Z; Guo Y; Zou CP
    Medicine (Baltimore); 2020 Feb; 99(7):e18332. PubMed ID: 32049776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
    Toral KJ; Wuenschel MA; Black EP
    PLoS One; 2021; 16(8):e0256416. PubMed ID: 34437586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.
    Lu Z; Yang S; Luo X; Shi Y; Lee JS; Deva S; Liu T; Chao Y; Zhang Y; Huang R; Xu Y; Shen Z; Shen L
    Gastric Cancer; 2022 Sep; 25(5):943-955. PubMed ID: 35778636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer.
    Thawani R; Agrawal N; Taflin NF; Kardosh A; Chen EY
    Oncologist; 2023 Jan; 28(1):40-47. PubMed ID: 36130326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TAPping Into PD-L1 Testing Efficiency for Gastroesophageal Cancer.
    Henick BS; Moy RH
    JCO Precis Oncol; 2024 Jul; 8():e2400344. PubMed ID: 39013136
    [No Abstract]   [Full Text] [Related]  

  • 32. Predictors for the clinical benefit of anti-PD-1/PD-L1 therapy in advanced gastroesophageal cancer: a meta-analysis of clinical trials.
    Zhuo ZG; Deng HY; Song TN; Alai GH; Shen X; Lin YD
    Ann Palliat Med; 2020 Sep; 9(5):2524-2537. PubMed ID: 33065778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
    Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
    Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy.
    Ji S; Chen H; Yang K; Zhang G; Mao B; Hu Y; Zhang H; Xu J
    Biomed Pharmacother; 2020 Sep; 129():110457. PubMed ID: 32887027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.
    Chen XJ; Yuan SQ; Duan JL; Chen YM; Chen S; Wang Y; Li YF
    Dis Markers; 2020; 2020():6717912. PubMed ID: 33488843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
    Zhong YM; Yin K; Chen Y; Xie Z; Lv ZY; Yang JJ; Yang XN; Zhou Q; Wang BC; Zhong WZ; Gao LL; Zhou WB; Chen J; Tu HY; Liao RQ; Zhang DK; Zhang SL; Lu DX; Zheng HB; Zhang HH; Wu YL; Zhang XC
    Front Immunol; 2022; 13():951817. PubMed ID: 36263036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Space-Time Continuum for Immunotherapy Biomarkers in Gastroesophageal Cancer?
    Klempner SJ; Upadhyay V; Chao J
    Clin Cancer Res; 2020 Dec; 26(24):6401-6403. PubMed ID: 33023951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
    Uruga H; Mino-Kenudson M
    Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimum immunotherapy method according to PD-L1 expression in advanced lung cancer: a network meta-analysis.
    Xiong L; Cai Y; Zhou X; Dai P; Wei Y; Zhao J; Tang H
    Future Oncol; 2022 Mar; 18(7):883-896. PubMed ID: 34825576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.